The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
Open accessPublished version of a preprint
Abstract
SARS-CoV-2 variants of concern (VOC) have arisen independently at multiple locations 1,2 and may reduce the efficacy of current vaccines that target the spike glycoprotein of SARS-CoV-2 3. Here, using a live-virus neutralization assay, we compared the neutralization of a non-VOC variant with the 501Y.V2 VOC (also known as B.1.351) using plasma collected from adults who were hospitalized with COVID-19 during the two waves of infection in South Africa, the second wave of which was dominated by infections with the 501Y.V2 variant. Sequencing demonstrated that infections of plasma donors from the first wave were with viruses that did not contain the mutations associated with 501Y.V2, except for one infection that contained the E484K substitution in the receptor-binding domain. The 501Y.V2 virus variant was effectively neutralized by plasma from individuals who were infected during the second wave. The first-wave virus variant was effectively neutralized by plasma from first-wave infections. However, the 501Y.V2 variant was poorly cross-neutralized by plasma from individuals with first-wave infections; the efficacy was reduced by 15.1-fold relative to neutralization of 501Y.V2 by plasma from individuals infected in the second wave. By contrast, cross-neutralization of first-wave virus variants using plasma from individuals with second-wave infections was more effective, showing only a 2.3-fold decrease relative to neutralization of first-wave virus variants by plasma from individuals infected in the first wave. Although we tested only one plasma sample from an individual infected with a SARS-CoV-2 variant with only the E484K substitution, this plasma sample potently neutralized both variants. The observed effective neutralization of first-wave virus by plasma from individuals infected with 501Y.V2 provides preliminary evidence that vaccines based on VOC sequences could retain activity against other circulating SARS-CoV-2 lineages.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, mutations in B.1.351 and P.1 variants are associated with the more pronounced loss of neutralizing capacity.15,16,22,23,25”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [25]
In the citing paper
“In addition, Beta and Delta are relatively poorly neutralized by convalescent sera obtained from unvaccinated individuals infected with non-VOC virus ( 7 – 9 , 21 ).”
From Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa (2021) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535
Self-citationDetection of a SARS-CoV-2 variant of concern in South Africa
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510
Self-citationAntibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853
Self-citationEvolution of antibody immunity to SARS-CoV-2
Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674
Self-citationSARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
Barnes, C. O., Jette, C. A., Abernathy, M. E., Dam, K.-M. A., Esswein, S. R., Gristick, H. B., Malyutin, A. G., Sharaf, N. G., Huey-Tubman, K. E., Lee, Y. E., et al. (2020) · Nature · doi:10.1038/s41586-020-2852-1 · Cited by 1,599
Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil
Faria, N. R., Mellan, T. A., Whittaker, C., Claro, I. M., Candido, D. D. S., Mishra, S., Crispim, M. A. E., Sales, F. C. S., Hawryluk, I., McCrone, J. T., et al. (2021) · Science · doi:10.1126/science.abh2644 · Cited by 1,461
Piccoli, L., Park, Y.-J., Tortorici, M. A., Czudnochowski, N., Walls, A. C., Beltramello, M., Silacci-Fregni, C., Pinto, D., Rosen, L. E., Bowen, J. E., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.037 · Cited by 1,395
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
Garcia-Beltran, W. F., Lam, E. C., St. Denis, K., Nitido, A. D., Garcia, Z. H., Hauser, B. M., Feldman, J., Pavlovic, M. N., Gregory, D. J., Poznansky, M. C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.013 · Cited by 1,353
Self-citation
Cited by
Sorted by citations
Items 201–300 of 657
Focosi, D., Tuccori, M., Baj, A., & Maggi, F. (2021) · Viruses · doi:10.3390/v13071211 · Cited by 37
Khan, K., Lustig, G., Bernstein, M. P., Archary, D., Cele, S., Karim, F., Smith, M., Ganga, Y., Jule, Z., Reedoy, K., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1008 · Cited by 37
Self-citationSun, C., Kang, Y., Liu, Y.-T., Kong, X., Xu, H.-Q., Xiong, D., Xie, C., Liu, Y., Peng, S., Feng, G., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00910-6 · Cited by 38
Mariën, J., Míchiels, J., Heyndríckx, L., Nkuba-Ndaye, A., Ceulemans, A., Bartholomeeusen, K., Madinga, J. N., Kingebeni, P. M., Vanlerberghe, V., Ahuka‐Mundeke, S., et al. (2021) · Journal of Virological Methods · doi:10.1016/j.jviromet.2021.114228 · Cited by 36
A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants
Pishesha, N., Harmand, T. J., Rothlauf, P. W., Praest, P., Alexander, R., van den Doel, R., Liebeskind, M. J., Vakaki, M. A., McCaul, N., Wijne, C., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2116147118 · Cited by 35
Lusvarghi, S., Wang, W., Herrup, R., Neerukonda, S. N., Vassell, R. A., Bentley, L., Eakin, A. E., Erlandson, K. J., & Weiss, C. D. (2021) · Journal of Virology · doi:10.1128/jvi.01110-21 · Cited by 33
Volk, A., Covini-Souris, C., Kühnel, D., de Mey, C., Römisch, J., & Schmidt, T. (2021) · BioDrugs · doi:10.1007/s40259-021-00511-9 · Cited by 35
de Castro, J. T., de Azevedo, P. O., Fumagalli, M. J., Hojo-Souza, N. S., Salazar, N., Almeida, G. G., Oliveira, L. I., Faustino, L., Antonelli, L. R. D. V., Marçal, T. G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32547-y · Cited by 37
SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodiesPreprint
Moyo-Gwete, T., Madzivhandila, M., Makhado, Z., Ayres, F., Mhlanga, D., Oosthuysen, B., Lambson, B., Kgagudi, P., Tegally, H., Iranzadeh, A., et al. (2021) · bioRxiv · doi:10.1101/2021.03.06.434193 · Cited by 134
Self-citationDetecting Rapid Spread of SARS-CoV-2 Variants, France, January 26–February 16, 2021
Haïm‐Boukobza, S., Roquebert, B., Trombert‐Paolantoni, S., Lecorché, E., Verdurme, L., Foulongne, V., Selinger, C., Michalakis, Y., Sofonea, M. T., & Alizon, S. (2021) · Emerging infectious diseases · doi:10.3201/eid2705.210397 · Cited by 35
Nguyen, D. V., Peter Simmonds, K., Steenhuis, M., Wouters, E., Desmecht, D. J.-M., Garigliany, M., Romano, M., Barbezange, C., Maes, P., Holm, B. V., et al. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.27.2100568 · Cited by 34
Epidemiological dynamics of SARS-CoV-2 VOC Gamma in Rio de Janeiro, Brazil
Moreira, F. R. R., D’arc, M., Mariani, D., Herlinger, A. L., Schiffler, F. B., Rossi, Á. D., Leitão, I. D. C., Miranda, T. D. S., Cosentino, M. A. C., Tôrres, M. C. D. P., et al. (2021) · Virus Evolution · doi:10.1093/ve/veab087 · Cited by 34
da Silva, S. J. R., de Lima, S. C., da Silva, R. C., Kohl, A., & Pena, L. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.836826 · Cited by 35
Role of the Microbiome in the Pathogenesis of COVID-19
De, R., & Dutta, S. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.736397 · Cited by 35
Neerukonda, S. N., Vassell, R. A., Lusvarghi, S., Wang, R., Echegaray, F., Bentley, L., Eakin, A. E., Erlandson, K. J., Katzelnick, L. C., Weiss, C. D., et al. (2021) · Viruses · doi:10.3390/v13122485 · Cited by 31
The Immune Response to SARS-CoV-2 and Variants of Concern
Torbati, E., Krause, K. L., & Ussher, J. E. (2021) · Viruses · doi:10.3390/v13101911 · Cited by 36
Bayarri‐Olmos, R., Johnsen, L. B., Idorn, M., Reinert, L. S., Rosbjerg, A., Vang, S., Hansen, C. B., Helgstrand, C., Bjelke, J. R., Bak-Thomsen, T., et al. (2021) · eLife · doi:10.7554/elife.70002 · Cited by 34
Yang, C.-Y., Chen, Y., Liu, P.-J., Hu, W., Lu, K., & Tsai, K. (2022) · International Journal of Medical Sciences · doi:10.7150/ijms.76168 · Cited by 33
Investigating the evolutionary origins of the first three SARS-CoV-2 variants of concern
Ghafari, M., Liu, Q., Dhillon, A., Katzourakis, A., & Weissman, D. B. (2022) · Frontiers in Virology · doi:10.3389/fviro.2022.942555 · Cited by 35
Lam, J. H., Shivhare, D., Chia, T. W., Chew, S. L., Sinsinbar, G., Aw, T. Y., Wong, S., Venkataraman, S., Lim, F. W. I., Vandepapelière, P., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c06350 · Cited by 33
Repeated vaccination and ‘vaccine exhaustion’: relevance to the COVID-19 crisis
Majumder, M. A. A., & Razzaque, M. S. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2071705 · Cited by 34
Ren, W., Ju, X., Gong, M., Lan, J., Yu, Y., Long, Q., Kenney, D., O’Connell, A. K., Zhang, Y. L., Zhong, J., et al. (2022) · mBio · doi:10.1128/mbio.00099-22 · Cited by 40
Immune response against SARS-CoV-2 variants: the role of neutralization assays
Chmielewska, A., Czarnota, A., Bieńkowska-Szewczyk, K., & Grzyb, K. (2021) · npj Vaccines · doi:10.1038/s41541-021-00404-6 · Cited by 34
SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa
Abdullahi, A., Oladele, D. A., Owusu, M., Kemp, S. A., James, A. B., Salako, A. O., Fink, D., Ige, F. A., Ferreira, I. A. T. M., Meng, B., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33792-x · Cited by 31
The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccinesPreprint
Liu, Y., Arase, N., Kishikawa, J.-I., Hirose, M., Li, S., Tada, A., Matsuoka, S., Arakawa, A., Akamatsu, K., Ono, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.22.457114 · Cited by 31
The consequences of SARS-CoV-2 within-host persistence
Sigal, A., Neher, R. A., & Lessells, R. J. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-024-01125-y · Cited by 39
Self-citationSeki, Y., Yoshihara, Y., Nojima, K., Momose, H., Fukushi, S., Moriyama, S., Wagatsuma, A., Numata, N., Sasaki, K., Kuzuoka, T., et al. (2022) · Med · doi:10.1016/j.medj.2022.04.013 · Cited by 30
Cocherie, T., Zafilaza, K., Leducq, V., Marot, S., Cálvez, V., Marcelin, A., & Todesco, È. (2022) · Microorganisms · doi:10.3390/microorganisms11010030 · Cited by 33
He, Q., Mao, Q., Peng, X., He, Z., Lu, S., Zhang, J., Gao, F., Bian, L., An, C., Yu, W., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00926-y · Cited by 31
Ferreira, I. A. T. M., Lee, C. Y. C., Foster, W. S., Abdullahi, A., Dratva, L. M., Tuong, Z. K., Stewart, B. J., Ferdinand, J. R., Guillaume, S. M., Potts, M., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112991 · Cited by 30
Beta SARS-CoV-2 variant and BNT162b2 vaccine effectiveness in long-term care facilities in France
Lefèvre, B., Tondeur, L., Madec, Y., Grant, R., Lina, B., van der Werf, S., Rabaud, C., Fontanet, A. L., & Legoff, A. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00230-0 · Cited by 29
Waning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccination
Tong, X., McNamara, R. P., Avendaño, M. J., Serrano, E. F., García‐Salum, T., Pardo‐Roa, C., Bertera, H. L., Chicz, T. M., Lévican, J., Poblete, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39189-8 · Cited by 38
da Silva, M. S., Demoliner, M., Hansen, A. W., Gularte, J. S., Silveira, F., Heldt, F. H., Filippi, M., Pereira, V. M. D. A. G., da Silva, F. P., Mallmann, L., et al. (2021) · Revista do Instituto de Medicina Tropical de São Paulo · doi:10.1590/s1678-9946202163058 · Cited by 30
Li, X., Zhang, L., Chen, S. E., Ji, W., Li, C., & Ren, L. (2021) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2021.104971 · Cited by 30
Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variantsPreprint
Ikegame, S., Siddiquey, M. N. A., Hung, C.-T., Haas, G. D., Brambilla, L., Oguntuyo, K. Y., Kowdle, S., Vilardo, A. E., Edelstein, A., Perandones, C., et al. (2021) · medRxiv · doi:10.1101/2021.03.31.21254660 · Cited by 30
Althaus, C. L., Baggio, S., Reichmuth, M. L., Hodcroft, E. B., Riou, J., Neher, R. A., Jacquérioz, F., Spechbach, H., Salamun, J., Vetter, P., et al. (2021) · medRxiv · doi:10.1101/2021.06.10.21258468 · Cited by 32
Self-citationEvolution of Antiviral Drug Resistance in SARS-CoV-2
Dinata, R., Baindara, P., & Mandal, S. M. (2025) · Viruses · doi:10.3390/v17050722 · Cited by 31
COVID-19 vaccines: progress and understanding on quality control and evaluation
Mao, Q., Xu, M., He, Q., Li, C., Meng, S., Wang, Y., Cui, B., Liang, Z., & Wang, J. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00621-4 · Cited by 29
Beta RBD boost broadens antibody-mediated protection against SARS-CoV-2 variants in animal models
Sheward, D. J., Mandolesi, M., Urgard, E., Kim, C., Hanke, L., Vidakovics, L. P., Pankow, A. P., Smith, N. L., Dopico, X. C., McInerney, G. M., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100450 · Cited by 28
Müller, M. K., Volzke, J., Subin, B., Müller, S. C., Sombetzki, M., Reisinger, E. C., & Müller‐Hilke, B. (2022) · BMC Medicine · doi:10.1186/s12916-022-02240-4 · Cited by 27
Goyal, A., Reeves, D. B., & Schiffer, J. T. (2022) · Journal of The Royal Society Interface · doi:10.1098/rsif.2021.0811 · Cited by 31
Su, W., Choy, K. T., Gu, H., Sia, S. F., Cheng, K. M., Nizami, S. I. N., Krishnan, P., Ng, Y. M., Chang, L. D. J., Liu, Y., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac276 · Cited by 27
Khan, R. U., Almakdi, S., Alshehri, M. S., Kumar, R., Ali, I., Hussain, S. M., Haq, A. U., Khan, I. U., Ullah, A., & Uddin, M. I. (2022) · Diagnostics · doi:10.3390/diagnostics12102539 · Cited by 29
Gabitzsch, E., Safrit, J. T., Verma, M. S., Rice, A., Sieling, P. A., Zakin, L., Shin, A., Morimoto, B., Adisetiyo, H., Wong, R. M. H., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.729837 · Cited by 24
Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIVPreprint
Alrubayyi, A., Gea‐Mallorquí, E., Touizer, E., Hameiri‐Bowen, D., Kopycinski, J. T., Charlton, B. G., Fisher-Pearson, N., Muir, L., Rosa, A., Roustan, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.15.431215 · Cited by 28
de Oliveira, T., Lutucuta, S., Nkengasong, J. N., Morais, J. F. M., Paixão, J., Neto, Z., Afonso, P., Miranda, J., David, K., Inglês, L., et al. (2021) · medRxiv · doi:10.1101/2021.03.30.21254323 · Cited by 27
Self-citationAge, Disease Severity and Ethnicity Influence Humoral Responses in a Multi-Ethnic COVID-19 Cohort
Smith, M., Abdesselem, H., Mullins, M. O., Tan, T.-M., Nel, A. J. M., Al‐Nesf, M. A., Bensmail, I., Majbour, N. K., Vaikath, N. N., Naik, A., et al. (2021) · Viruses · doi:10.3390/v13050786 · Cited by 27
Hussey, H., Zinyakatira, N., Morden, E., Ismail, M., Paleker, M., Bam, J.-L., London, L., Boulle, A., & Davies, M.-A. (2021) · Gates Open Research · doi:10.12688/gatesopenres.13288.1 · Cited by 27
Tallei, T. E., Fatimawali, F., Adam, A. A., Elseehy, M. M., El‐Shehawi, A. M., Mahmoud, E. A., Tania, A. D., Niode, N. J., Kusumawaty, D., Rahimah, S., et al. (2022) · Molecules · doi:10.3390/molecules27010260 · Cited by 29
Li, J., Wu, Y., Zhang, S., Kang, X., & Jiang, T. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac036 · Cited by 28
Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variantsPreprint
Ikegame, S., Siddiquey, M. N. A., Hung, C.-T., Haas, G. D., Brambilla, L., Oguntuyo, K. Y., Kowdle, S., Vilardo, A. E., Edelstein, A., Perandones, C., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-400230/v1 · Cited by 27
Jodaylami, M. H., Djaïleb, A., Ricard, P., Lavallée, É., Cellier-Goetghebeur, S., Parker, M.-F., Coutu, J., Stuible, M., Gervais, C., Durocher, Y., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-00844-z · Cited by 28
Greaney, A. J., Eguia, R. T., Starr, T. N., Khan, K., Franko, N., Logue, J. K., Lord, S. M., Speake, C., Chu, H. Y., Sigal, A., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010592 · Cited by 29
Self-citationWurtzer, S., Levert, M., Dhenain, E., Accrombessi, H., Manco, S., Fagour, N., Goulet, M., Boudaud, N., Gaillard, L., Bertrand, I., et al. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.157740 · Cited by 25
Lan, J., Chen, P., Liu, W., Ren, W., Zhang, L., Ding, Q., Zhang, Q., Wang, X., & Ge, J. (2022) · Structure · doi:10.1016/j.str.2022.07.005 · Cited by 25
Antigenic evolution of SARS-CoV-2 in immunocompromised hosts
Smith, C. A., & Ashby, B. (2022) · Evolution Medicine and Public Health · doi:10.1093/emph/eoac037 · Cited by 26
Fang, L., Xu, J., Zhao, Y., Fan, J., Shen, J., Liu, W., & Cao, G. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1228128 · Cited by 26
Wagner, R., Meißner, J., Grabski, E., Sun, Y., Vieths, S., & Hildt, E. (2021) · Allergy · doi:10.1111/all.14868 · Cited by 25
Denaturation of the SARS-CoV-2 spike protein under non-thermal microwave radiation
Afaghi, P., Lapolla, M. A., & Ghandi, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-02753-7 · Cited by 23
Chibwana, M. G., Moyo-Gwete, T., Kwatra, G., Mandolo, J. J., Hermanaus, T., Motlou, T. P., Mzindle, N. B., Ayres, F., Chaponda, M., Tembo, G., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02342-z · Cited by 23
Rapid identification of neutralizing antibodies against SARS-CoV-2 variants by mRNA display
Tanaka, S., Olson, C. A., Barnes, C. O., Higashide, W., Gonzalez, M. R., Taft, J. D., Richardson, A., Martín-Fernández, M., Bogunovic, D., Gnanapragasam, P. N. P., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110348 · Cited by 20
Vimalanathan, S., Shehata, M., Kannan, S., Delbue, S., Dolci, M., Pariani, E., D’Alessandro, S., & Pleschka, S. (2022) · Microorganisms · doi:10.3390/microorganisms10112145 · Cited by 24
Addetia, A., Park, Y., Starr, T. N., Greaney, A. J., Sprouse, K. R., Bowen, J. E., Tilles, S. W., Voorhis, W. C. V., Bloom, J. D., Corti, D., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112621 · Cited by 24
Karim, F., Riou, C., Bernstein, M. P., Jule, Z., Lustig, G., van Graan, S., Keeton, R., Upton, J., Ganga, Y., Khan, K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46673-2 · Cited by 26
Self-citationCohen, J. A., Stuart, R. M., Rosenfeld, K., Lyons, H. M., White, M. T., Kerr, C. C., Klein, D. J., & Famulare, M. (2021) · medRxiv · doi:10.1101/2021.05.31.21258018 · Cited by 21
Di, A., Cunha, F., Petrosillo, N., Beeching, N. J., Ergonul, O., Petersen, E., & Koopmans, M. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.03.011 · Cited by 24
Boulton, S., Poutou, J., Martin, N. T., Azad, T., Singaravelu, R., Crupi, M. J. F., Jamieson, T. R., He, X., Marius, R. M., Petryk, J., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.10.008 · Cited by 24
Ali, M. A., Zhang, F., Hu, C., Yuan, B., Jahan, S., Kitsios, G. D., Morris, A., Gao, S., & Panat, R. P. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28075 · Cited by 24
Research progress in spike mutations of SARS‐CoV‐2 variants and vaccine development
He, X., He, C., Hong, W., Yang, H. J., & Wei, X. (2023) · Medicinal Research Reviews · doi:10.1002/med.21941 · Cited by 25
Phenotypic evolution of SARS-CoV-2 spike during the COVID-19 pandemic
Furnon, W., Cowton, V. M., Lorenzo, G. D., Orton, R. J., Herder, V., Cantoni, D. M., Ilia, G., Mendonça, D. C., Kerr, K., Allan, J., et al. (2025) · Nature Microbiology · doi:10.1038/s41564-024-01878-5 · Cited by 23
Hoffmann, S., Schrezenmeier, E. V., Desmarets, M., Halleck, F., Dürrbach, A., Peters, L., Tremmel, A.-T., Seidel, A., Führer, M., Bachmann, F., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105613 · Cited by 22
Pattabiraman, C., Prasad, P., George, A. K., Sreenivas, D., Rasheed, R., Reddy, N. V. K., Desai, A. S., & Ravi, V. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16768.1 · Cited by 21
Jaafar, R., Boschi, C., Aherfi, S., Bancod, A., Bideau, M. L., Edouard, S., Colson, P., Chahinian, H., Raoult, D., Yahi, N., et al. (2021) · Viruses · doi:10.3390/v13112177 · Cited by 22
Hirotsu, Y., Amemiya, K., Sugiura, H., Shinohara, M., Takatori, M., Mochizuki, H., & Omata, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.722766 · Cited by 22
Erster, O., Mendelson, E., Levy, V., Kabat, A., Mannasse, B., Asraf, H., Azar, R., Ali, Y., Shirazi, R., Bucris, E. D., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00506-21 · Cited by 21
Egeren, D. V., Novokhodko, A., Stoddard, M., Tran, U., Zetter, B. R., Rogers, M. S., Joseph‐McCarthy, D., & Chakravarty, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-02148-8 · Cited by 20
COVID-19 Vaccine: Between Myth and Truth
Piccaluga, P. P., Guardo, A. D., Lagni, A., Lotti, V., Diani, E., Navari, M., & Gibellini, D. (2022) · Vaccines · doi:10.3390/vaccines10030349 · Cited by 22
Multiplex Fragment Analysis for Flexible Detection of All SARS-CoV-2 Variants of Concern
Clark, A. E., Wang, Z., Ostman, E., Zheng, H., Yao, H., Cantarel, B. L., Kanchwala, M., Xing, C., Chen, L., Irwin, P., et al. (2022) · Clinical Chemistry · doi:10.1093/clinchem/hvac081 · Cited by 23
Upgrading nirmatrelvir to inhibit SARS-CoV-2 Mpro via DeepFrag and free energy calculations
Tâm, N. M., Nguyen, T. H., Pham, M. Q., Hong, N. D., Tùng, N. T., Vu, V. V., Quang, D. T., & Ngô, S. T. (2023) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2023.108535 · Cited by 22
Horspool, A. M., Ye, C., Wong, T. Y., Russ, B. P., Lee, K. S., Winters, M. T., Bevere, J. R., Kieffer, T. W., Martínez, I., Sourimant, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.05.442784 · Cited by 22
Fiolet, T., Kherabi, Y., MacDonald, C. J., Ghosn, J., & Peiffer‐Smadja, N. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/z4x7t · Cited by 22
COVID‐19: emergence and mutational diversification of SARS‐CoV‐2
Brüssow, H. (2021) · Microbial Biotechnology · doi:10.1111/1751-7915.13800 · Cited by 23
High‐resolution melting curve FRET‐PCR rapidly identifies SARS‐CoV‐2 mutations
Barua, S., Hoque, M. M., Kelly, P. J., Bai, J., Hanzlicek, G., Noll, L. W., Walz, H., Johnson, C. M., Kyriakis, C. S., & Wang, C. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27139 · Cited by 21
Furukawa, K., Tjan, L. H., Sutandhio, S., Kurahashi, Y., Iwata, S., Tohma, Y., Sano, S., Nakamura, S., Nishimura, M., Arii, J., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab430 · Cited by 22
VIRFIM: an AI and Internet of Medical Things-driven framework for healthcare using smart sensors
Khowaja, S. A., Khuwaja, P., Dev, K., & D’Aniello, G. (2021) · Neural Computing and Applications · doi:10.1007/s00521-021-06434-4 · Cited by 22
SARS-CoV-2 Infection of Rhesus Macaques Treated Early with Human COVID-19 Convalescent Plasma
Deere, J. D., Carroll, T. D., Dutra, J., Fritts, L., Sammak, R. L., Yee, J. L., Olstad, K. J., Reader, J. R., Kistler, A. L., Kamm, J., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01397-21 · Cited by 19
van der Velden, Y. U., Grobben, M., Caniels, T. G., Burger, J. A., Poniman, M., Oomen, M., Rijnstra, E. S.-V., Tejjani, K., Guerra, D., Kempers, R., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-07590-w · Cited by 21
Shen, A.-R., Jin, X.-X., Tang, T.-T., Ding, Y., Liu, X.-T., Zhong, X., Wu, Y.-D., Han, X.-L., Zhao, G.-Y., Shen, C.-L., et al. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s367494 · Cited by 19
Chaturvedi, S., Beutler, N., Vasen, G., Pablo, M., Chen, X., Calia, G., Buie, L., Rodick, R., Smith, D. M., Rogers, T. F., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204624119 · Cited by 22
The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillancePreprint
Tegally, H., San, J. E., Cotten, M. L., Tegomoh, B., Mboowa, G., Martin, D. P., Baxter, C., Moir, M., Lambisia, A. W., Diallo, A. B., et al. (2022) · medRxiv · doi:10.1101/2022.04.17.22273906 · Cited by 21
Self-citationRapid genome sequencing in hospitals to identify potential vaccine-escape SARS-CoV-2 variants
Snell, L. B., Cliff, P. R., Charalampous, T., Alcolea-Medina, A., Ebie, S. A. R. T., Sehmi, J. K., Flaviani, F., Batra, R., Douthwaite, S. T., Edgeworth, J. D., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00482-5 · Cited by 20
Application of omics technology to combat the COVID‐19 pandemic
Yang, J., Yan, Y., & Zhong, W. (2021) · MedComm · doi:10.1002/mco2.90 · Cited by 20
Heterologous humoral immunity to human and zoonotic coronaviruses: Aiming for the achilles heel
Ng, K. W., Faulkner, N., Wrobel, A. G., Gamblin, S. J., & Kassiotis, G. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101507 · Cited by 19
Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus
Amanat, F., Strohmeier, S., Meade, P. S., Dambrauskas, N., Mühlemann, B., Smith, D. J., Vigdorovich, V. I., Sather, D. N., Coughlan, L., & Krammer, F. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001384 · Cited by 20
A spatial vaccination strategy to reduce the risk of vaccine-resistant variants
Zhang, X., Lobinska, G., Feldman, M., Dekel, E., Nowak, M. A., Pilpel, Y., Pauzner, Y., Barzel, B., & Pauzner, A. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010391 · Cited by 22
Fillâtre, P., Dufour, M.-J., Behillil, S., Vatan, R., Reusse, P., Gabellec, A., Velmans, N., Montagne, C., Coudret, S. G. D., Droumaguet, E., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.035 · Cited by 21
Winkler, M. S., Claus, R. A., Schilder, M., Pöhlmann, S., Coldewey, S. M., Grundmann, J., Fricke, T., Moerer, O., Meissner, K., Bauer, M. W., et al. (2021) · Clinical Science · doi:10.1042/cs20210666 · Cited by 20
Structural basis of nanobodies neutralizing SARS-CoV-2 variants
Shi, Z., Li, X., Wang, L., Sun, Z., Zhang, H., Chen, X., Cui, Q., Qiao, H., Lan, Z., Zhang, X., et al. (2022) · Structure · doi:10.1016/j.str.2022.02.011 · Cited by 19
HIV skews the SARS-CoV-2 B cell response towards an extrafollicular maturation pathway
Krause, R., Snyman, J., Hwa, S.-H., Muema, D., Karim, F., Ganga, Y., Ngoepe, A., Zungu, Y., Gazy, I., Bernstein, M. P., et al. (2022) · eLife · doi:10.7554/elife.79924 · Cited by 21
Self-citationRichard, D., Shaw, L. P., Lanfear, R., Corbett-Detig, R. B., Hinrichs, A. S., McBroome, J., Turakhia, Y., Acman, M., Owen, C. J., Tan, C. C. S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.06.442903 · Cited by 20
Metadata
- Authors
- Network for Genomic Surveillance in South Africa, Cele, S., COMMIT-KZN Team, Gazy, I., Jackson, L., Hwa, S.-H., Tegally, H., Lustig, G., Giandhari, J., Pillay, S., Wilkinson, E., Naidoo, Y., Karim, F., Ganga, Y., Khan, K., Bernstein, M., Balazs, A. B., Gosnell, B. I., Hanekom, W., Moosa, M.-Y. S., Lessells, R. J., de Oliveira, T., & Sigal, A.
- Affiliations
- Africa Health Research Institute (ZA)
- Hebrew University of Jerusalem (IL)
- Centre for the AIDS Programme of Research in South Africa (ZA)
- University of KwaZulu-Natal (ZA)
- Ragon Institute of MGH, MIT and Harvard (US)
- Max Planck Institute for Infection Biology (DE)
- Corresponding author
- Sigal, Alex
- ORCID
- Cele, Sandile
- Gazy, Inbal
- Jackson, Laurelle
- Hwa, Shi-Hsia
- Tegally, Houriiyah
- Lustig, Gila
- Giandhari, Jennifer
- Pillay, Sureshnee
- Wilkinson, Eduan
- Naidoo, Yeshnee
- Karim, Farina
- Ganga, Yashica
- Khan, Khadija
- Bernstein, Mallory
- Balazs, Alejandro B.
- Gosnell, Bernadett I.
- Hanekom, Willem
- Moosa, Mahomed-Yunus S.
- Lessells, Richard J.
- de Oliveira, Tulio
- Sigal, Alex
- Venue
- Nature
- Published
- 2021-03-29
- Volume
- 593
- Issue
- 7857
- Pages
- 142-146
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC9867906
- OpenAlex
- W3148277587
- Cited by
- 651
- References
- 31
- Citations by year
- 2026: 13 · 2025: 22 · 2024: 28 · 2023: 63 · 2022: 199 · 2021: 320
- FWCI
- 48.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature (publishedVersion)
- medRxiv (acceptedVersion, cc-by-nd)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Griffith Research Online (submittedVersion, other-oa)
- Funders
- South African Medical Research Council
- Inyuvesi Yakwazulu-Natali
- National Health Laboratory Service
- Medical Research Council
- National Institute on Drug Abuse (DP2DA040254)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Keywords
- SARS-CoV-2, Beta variant, convalescent plasma, neutralizing antibodies, cross-neutralization, vaccine efficacy, spike protein, receptor binding domain, COVID-19 pandemic, South Africa
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Serotherapy, Animals, Antibodies, Viral, Cell Line, Chlorocebus aethiops, Humans, Immunization, Passive, Mutation, Neutralization Tests, South Africa, Time Factors, Vero Cells, Immune Evasion, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
